undamentalytics Newsletter
Sign in

Whitehawk Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Whitehawk Therapeutics, Inc. had total assets of $151m, total liabilities of $14.5m and shareholders' equity of $136m. It held $37.6m in cash against $0 of debt: net cash of $37.6m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents633941493963293885
Receivables——1402560—
Inventory———02650—
Total current assets64401915118012561149192
Total assets64401915818413270151194
Accounts payable102646211
Total current liabilities5330151926171511
Long-term debt——1——————
Total debt0010—00000
Total liabilities5331222627181511
Shareholders' equity59−9−1213615810552136183
Non-controlling interests and other (assets − liabilities − equity)—46———————
Net debt (negative = net cash)−63−396−149−39−63−29−38−85
Shares outstanding——3m—24m25m25m——

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Whitehawk Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Whitehawk Therapeutics, Inc.